Drug Profile
Research programme: human cytomegalovirus infections therapeutics - AiCuris
Alternative Names: AIC 813; HCMV therapeutics - AiCurisLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator AiCuris
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cytomegalovirus infections in Germany (unspecified route)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Germany
- 06 Sep 2016 The research programme is still in preclinical development for Cytomegalovirus infections (AiCuris pipeline, September 2016)